+ Site Statistics
References:
52,572,879
Abstracts:
28,705,754
PMIDs:
27,750,366
DOIs:
25,464,004
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Is immunological therapy useful in chronic hepatitis C virus infection? A randomized study of interferon alpha2a plus cimetidine versus interferon alpha2a plus placebo



Is immunological therapy useful in chronic hepatitis C virus infection? A randomized study of interferon alpha2a plus cimetidine versus interferon alpha2a plus placebo



Hepatology 32(4 Pt 2): 443A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035183928

Download citation: RISBibTeXText


Related references

A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Alimentary Pharmacology & Therapeutics 19(3): 339-347, 2004

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. Scandinavian Journal of Gastroenterology 34(2): 194-198, 1999

Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection. Antiviral Therapy 13(7): 851-862, 2008

Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group. Journal of Viral Hepatitis 5(1): 53-59, 1998

A randomized controlled trial of kurorinone versus interferon-alpha2a treatment in patients with chronic hepatitis B. Journal of Viral Hepatitis 7(3): 225-229, 2000

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49(6): 1847-1858, 2009

Extracorporeal photopheresis alone and with interferon-alpha2a in chronic hepatitis C patients who failed previous interferon therapy. Digestive Diseases and Sciences 44(5): 1020-1026, 1999

Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection. Antiviral Therapy 9(1): 23-26, 2004

Comparison of two different regimens of combined interferon-alpha2a and lamivudine therapy in children with chronic hepatitis B infection. Antiviral Therapy 11(2): 255-261, 2006

Efficacy and safety of escitalopram, for the prevention of depressive episodes induced by PEG-interferon alpha2a and ribavirin in chronic hepatitis C patients. A double-blind, randomized, placebo-controlled trial. 2007

Importance of pretreatment viral load and monitoring of serum hepatitis C virus RNA in predicting responses to interferon-alpha2a treatment of chronic hepatitis C. Hanshin Chronic Hepatitis C Study Group. Journal of Interferon and Cytokine Research 17(11): 707-712, 1997

A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Alimentary Pharmacology and Therapeutics 24(7): 1079-1086, 2006

Pegylated interferon alpha2b versus pegylated interferon alpha2a for chronic hepatitis C: the unreached goal of superiority. Journal of Hepatology 51(6): 1097-1099, 2009

Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection. Methods and Findings in Experimental and Clinical Pharmacology 27(5): 317-322, 2005

Bedeutung der immunochemotherapie fur das uberleben von patienten mit metastasiertem nierenzellkarzinom - Eine retrospektive studie der therapie-gruppen interferon-alpha2a/vinblastin vs. interferon-alpha2a/interleukin-2/5-fluorouracil. Urologe A 43(9): 1111-1119, 2004